The Life Sciences team advised Relay Therapeutics on the completion of its $400 million Series C financing round. Proceeds from this financing are anticipated to be used to accelerate the implementation of Relay Therapeutics’ long-term strategy. It will also support the expansion of the company’s discovery efforts, advance existing programs into the clinic and bolster its broad platform and diverse team.
The financing was led by the SoftBank Vision Fund and included participation from additional new investors including Foresite Capital, Perceptive Advisors and Tavistock Group. Existing investors GV, Casdin Capital, BVF Partners, EcoR1 Capital, Alexandria Venture Investments, and an affiliate of D.E. Shaw Research also participated in the round.
Relay Therapeutics is committed to creating medicines that will have a transformative impact on patients by building a unique discovery platform centered on understanding how the conformation of proteins relate to function.
The Goodwin team was led by partner William Collins and included partners Mitchell Bloom, Janet Andolina, Paul Jin and Richard Matheny; counsels Sonita Bennitt, Todd Hahn and Jacob Osborn; and associates Shoaib Ghias, Gabriela Morales-Rivera, Jason Goldfarb and Leslie Jaw and Matthew Wheatley.
For additional information on the financing, please read the press release.